Journal articleBMC Cancer2018
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
- Journal
- BMC Cancer
- Published
- 29 November 2018
- Citations
- 27
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Trials 3
- BackgroundA Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Cl… NCT02670746↗
- BackgroundTreatment of Pancreatic Cancer With Abraxane NCT02555813↗
- BackgroundNab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (t… NCT01964430↗